Nicholas J. Cowans

First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery Doppler pulsatility index as markers of pre-eclampsia.

To evaluate whether measurement of maternal serum placental protein‐13 (PP‐13) and pregnancy‐associated plasma protein‐A (PAPP‐A) at 11 + 0 to 13 + 6 weeks of gestation alone or in combination with second‐trimester uterine artery pulsitility measured by Doppler velocimetry is useful in predicting those women who will develop pre‐eclampsia

First‐trimester biochemical markers of aneuploidy and the prediction of small‐for‐gestational age fetuses

To examine the clinical utility of the first‐trimester biochemical markers of aneuploidy in their ability to predict subsequent delivery of a small‐for‐gestational age (SGA) infant.

First‐trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery

To examine the clinical utility of the first‐trimester markers of aneuploidy in their ability to predict preterm delivery.

First-trimester markers for the prediction of pre-eclampsia in women with a-priori high risk

To investigate the predictive value of the combination of first‐trimester serum placental protein 13 (PP13), uterine artery Doppler pulsatility index (PI) and pulse wave analysis (augmentation index at a heart rate of 75 beats per min (AIx‐75)), and to evaluate concurrent and contingent strategies using this combination for assessing the risk of pre‐eclampsia in high‐risk women.

First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death.

To examine the clinical utility of the first‐trimester markers of aneuploidy in their ability to predict future fetal loss.

ADAM12s in maternal serum as a potential marker of pre-eclampsia.

To examine whether maternal serum ADAM12s, a potential first‐ and second‐trimester marker of fetal aneuploidy and fetal growth, had altered concentrations in the first or second trimester of pregnancies subsequently developing pre‐eclampsia.

ADAM 12 as a first‐trimester maternal serum marker in screening for Down syndrome

A Disintegrin And Metalloprotease 12 (ADAM 12) is a glycoprotein synthesised by placenta and it has been shown to be a potential first‐trimester maternal serum marker for Down syndrome (DS) in two small series. Here we analyse further, the potential of ADAM 12 as a marker for DS in a large collection of first‐trimester serum samples.

First trimester maternal serum placental protein 13 for the prediction of pre-eclampsia in women with a priori high risk.

To evaluate whether first trimester maternal serum PP13 can predict pre‐eclampsia among women with a priori high risk.

Maternal serum inhibin-A and activin-A levels in the first trimester of pregnancies developing pre-eclampsia

To evaluate whether measurement of maternal serum inhibin‐A and activin‐A at 11 + 0 to 13 + 6 weeks of gestation, alone or in combination with second‐trimester uterine artery pulsatility measured by Doppler velocimetry, is useful in predicting those women who will develop pre‐eclampsia.

First-trimester maternal placental protein 13 levels in pregnancies resulting in adverse outcomes.

In a previous study, reduced levels of maternal serum placental protein 13 (PP13) in the first trimester have been correlated with adverse pregnancy outcomes. The objective of this study was to compare first‐trimester PP13 levels in control pregnancies with pregnancies resulting in one or more of the following adverse outcomes: intrauterine growth restriction (IUGR), small and very small (3rd, 5th, 10th centile) for gestational age (SGA), low (<1.5 and < 2.5 kg) birth weight (LBW), macrosomia (the > 90th centile), large birth weight (>4.5 kg), preterm (35–36 weeks) and very early (<34 weeks) delivery (PTD), and intrauterine fetal demise (IUFD).